Secondary hyperparathyroidism of uremia is associated with poor health outcomes, including all-cause mortality, cardiovascular mortality, and fractures. Standard therapy for secondary hyperparathyroidism includes vitamin D receptor activators, and phosphate binders. Persistently elevated parathyroid hormone(PTH)levels may require the addition of calcimimetics which sensitizes calcium-sensing receptors on the parathyroid glands.
Yasuo Imanishi. Oral calcimimetics on secondary hyperparathyroidism of uremia. Clinical calcium. 2017;27(4):561-566
PMID: 28336833
View Full Text